Skip to main content

Table 2 Analysis of the parasitaemia results of 17 specimens containing Plasmodium falciparum

From: Estimating the parasitaemia of Plasmodium falciparum: experience from a national EQA scheme

No

Reference mean parasitaemia

Participants mean parasitaemia

Standard deviation

No. and % of participants reporting parasitaemia > reference mean

% over estimating parasitaemia

% under estimating parasitaemia

% not specifying parasitaemia

Incorrect Plasmodium species reported

1

0.1%

0.5%

0.4

136 (62%)

12%

0%

22 (10%)

P. vivax 16/217 (7%)

P. ovale 10/217 (5%)

2

0.25%

0.4%

0.3

105 (49%)

17%

0%

50 (19%)

P. vivax 44 (17%)

P. ovale 37 (14%)

P. malariae 13 (5%)

3

1.1%

1.4%

0.57

116 (42%)

18%

5%

NA*

None

4

1.4%

1.5%

0.69

85 (43%)

14%

2%

74 (27%)

P. vivax 1/198 (0.3%)

P. malariae 1 (0.3%)

5

1.8%

2.3%

0.8

123 (59%)

15%

10%

58 (22%)

P. vivax 15/266 (6%)

P. ovale 5

(2 %)

P. malariae 3 (1%)

6

2.5%

2.8%

1.3

75 (44%)

11%

8%

NA*

P. vivax 5/170 (3%)

P. ovale 2/170 (1%)

7

2.5%

3%

1.3

127 (62%)

14%

3%

66 (24%)

P. vivax 10/271 (4%)

P. ovale 1 (0.4%)

P. malariae 2 (0.7%)

8

2.5%

3%

1

138 (66%)

19%

2%

49 (19%)

P. vivax 7 (3%)

9

3%

3.5%

1.1

68 (66%)

12%

4%

170 (54%)

P. malariae 1/236 (0.4%)

10

5%

5.8%

2

91 (51%)

13%

10%

66 (27%)

P. vivax 3/243 (1%)

P. ovale 4 (1.6%)

P. malariae 20 (8%)

11

7.5%

11.8%

4.4

98 (35%)

9%

4%

NA*

P. ovale 1/115 (1%)

12

9%

9.2%

2.5

92 (45%)

20%

19%

53 (21%)

None

13

10.5%

11.5%

3.4

96 (54%)

30%

3%

79 (31%)

P. ovale 1/256 (0.4%)

P. malariae 1 (0.4%)

14

16%

18%

4.5

130 (57%)

35%

3%

9 (4%)

P. vivax 2/226 (1%)

15

20%

24.2%

4.6

99 (46%)

33%

4%

NA*

None

16

20%

20.8%

6.7

120 (40%)

25%

0

NA*

P. vivax 1/300 (0.3%)

17

30%

32%

10

80(39%)

10%

25%

52 (21%)

P. vivax 1/253 (0.4%)

(Babesia sp. 4 (2%))

  1. NA* Not applicable (see text below). Specimen 8 also contained trophozoites of P. ovale and specimen 14 also contained trophozoites of P.vivax.